Login Register Cart 0
Generic placeholder image

Current Reviews in Clinical and Experimental Pharmacology

Editor-in-Chief

ISSN (Print): 2772-4328
ISSN (Online): 2772-4336

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Review Article

Predictability of Elimination and Excretion of Small Molecules in Animals and Humans, and its Impact on Dosimetry for human ADME Studies with Radiolabeled Drugs

Author(s): Ad Roffel*, Jan Jaap van Lier, Gerk Rozema and Ewoud-Jan van Hoogdalem

Volume 17, Issue 1, 2022

Published on: 08 March, 2021

Page: [26 - 38] Pages: 13

DOI: 10.2174/1574884716666210309103625

Price: $65

Abstract

Background: We assessed the extent to which urinary and fecal excretion of 14C-labeled drug material in animal ADME studies was predictive of human ADME studies. We compared observed plasma elimination half-lives for total drug-related radioactivity in humans to pre-study predictions, and we estimated the impact of any major differences on human dosimetry calculations.

Methods: We included 34 human ADME studies with doses of 14C above 0.1 MBq. We calculated ratios of dosimetry input parameters (percentage fecal excretion in humans versus animals; observed half-life in humans versus predicted pre-study) and output parameters (effective dose post-study versus pre-study) and assessed their relationship.

Results: A quantitative correlation assessment did not show a statistically significant correlation between the ratios of percentages of 14C excreted in feces and the ratios of dosimetry outcomes in the entire dataset, but a statistically significant correlation was found when assessing the studies that were based on ICRP 60/62 (n=19 studies; P=0.0028). There also appeared to be a correlation between the plasma half-life ratios and the ratios of dosimetry results. A quantitative correlation assessment showed that there was a statistically significant correlation between these ratios (P<0.0001).

Conclusion: In all cases where the plasma elimination half-life for 14C in humans was found to be longer than the predicted value, the radiation burden was still within ICRP Category IIa. Containment of the actual radiation burden below the limit of 1.00 mSv appeared to be determined partly also by our choice to limit 14C doses to 3.7 MBq.

Keywords: Dosimetry, ADME, excretion, 14C, ICRP, effective dose.

« Previous Next »
Graphical Abstract

[1]
Roffey SJ, Obach RS, Gedge JI, Smith DA. What is the objective of the mass balance study? A retrospective analysis of data in animal and human excretion studies employing radiolabeled drugs. Drug Metab Rev 2007; 39(1): 17-43.
[http://dx.doi.org/10.1080/03602530600952172] [PMID: 17364879]
[2]
Penner N, Klunk LJ, Prakash C. Human radiolabeled mass balance studies: Objectives, utilities and limitations. Biopharm Drug Dispos 2009; 30(4): 185-203.
[http://dx.doi.org/10.1002/bdd.661] [PMID: 19544285]
[3]
Obach RS, Nedderman AN, Smith DA. Radiolabelled mass-balance excretion and metabolism studies in laboratory animals: Are they still necessary? Xenobiotica 2012; 42(1): 46-56.
[http://dx.doi.org/10.3109/00498254.2011.621985] [PMID: 21992031]
[4]
Roffel AF, van Marle SP, van Lier JJ, Hartstra J, van Hoogdalem E-J. An evaluation of human ADME and mass balance studies using regular or low doses of radiocarbon. J Labelled Comp Radiopharm 2016; 59(14): 619-26.
[http://dx.doi.org/10.1002/jlcr.3473] [PMID: 28000265]
[5]
James A, Blumenstein L, Glaenzel U, et al. Absorption, distribution, metabolism, and excretion of [(14)C]BYL719 (alpelisib) in healthy male volunteers. Cancer Chemother Pharmacol 2015; 76(4): 751-60.
[http://dx.doi.org/10.1007/s00280-015-2842-4] [PMID: 26254025]
[6]
Pearson D, Weiss HM, Jin Y, et al. Absorption, distribution, metabolism and excretion of the oral prostaglandin D2 receptor 2 (DP2) antagonist fevipiprant (QAW039) in healthy volunteers and in vitro. Drug Metab Dispos 2017; 45(7): 817-25.
[http://dx.doi.org/10.1124/dmd.117.075358] [PMID: 28442499]
[7]
Ufer M, Huynh C, van Lier JJ, Caroff E, Fischer H, Dingemanse J. Absorption, distribution, metabolism and excretion of the P2Y12 receptor antagonist selatogrel after subcutaneous administration in healthy subjects. Xenobiotica 2020; 50(4): 427-34.
[http://dx.doi.org/10.1080/00498254.2019.1646440] [PMID: 31322041]
[8]
Fox GM, Roffel AF, Hartstra J, Bussian LA, van Marle SP. Metabolism and excretion of intravenous, radio-labeled amisulpride in healthy, adult volunteers. Clin Pharmacol 2019; 11: 161-9.
[http://dx.doi.org/10.2147/CPAA.S234256] [PMID: 31819674]
[9]
Beaumont C, Young GC, Cavalier T, Young MA. Human absorption, distribution, metabolism and excretion properties of drug molecules: A plethora of approaches. Br J Clin Pharmacol 2014; 78(6): 1185-200.
[http://dx.doi.org/10.1111/bcp.12468] [PMID: 25041729]
[10]
Schadt S, Bister B, Chowdhury SK, et al. A decade in the MIST: learnings from investigations of drug metabolites in drug development under the “Metabolites in Safety Testing” regulatory guidance. Drug Metab Dispos 2018; 46(6): 865-78.
[http://dx.doi.org/10.1124/dmd.117.079848] [PMID: 29487142]
[11]
International commission on radiological protection. Publication 60: 1990 recommendations of the international commission on radiological protection. Ann ICRP 1991; 21(1-3): 1-201.
[12]
International commission on radiological protection. Publication 62: Radiological protection in biomedical research. Ann ICRP 1991; 22: 3.
[13]
International commission on radiological protection. Publication 100: Human alimentary tract model for radiological protection. Ann ICRP 2006; 36: 1-2.
[14]
International commission on radiological protection. Publication 103: The 2007 recommendations of the international commission on radiological protection. Ann ICRP 2007; 37: 2-4.
[15]
Center for Drug Evaluation and Research, Food and Drug Administration, U.S. Department of Health and Human Services. 2020. Available at: www.fda.gov/regulatory-information/search-fda-guidance-documents/safety-testing-drug-metabolites
[16]
Kimoto E, Bi Y-A, Kosa RE, Tremaine LM, Varma MVS. Hepatobiliary clearance prediction: species scaling from monkey, dog, and rat, and in vitro - in vivo extrapolation of sandwich-cultured human hepatocytes using 17 drugs. J Pharm Sci 2017; 106(9): 2795-804.
[http://dx.doi.org/10.1016/j.xphs.2017.04.043] [PMID: 28456723]
[17]
Leenaars CHC, Kouwenaar C, Stafleu FR, et al. Animal to human translation: A systematic scoping review of reported concordance rates. J Transl Med 2019; 17(1): 223-44.
[http://dx.doi.org/10.1186/s12967-019-1976-2] [PMID: 31307492]

Rights & Permissions Print Cite
Article Metrics
17
2
1
1
© 2024 Bentham Science Publishers | Privacy Policy